News
GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...
10d
News-Medical.Net on MSNGLP-1 agonists may reshape the gut microbiomeResearch reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...
The Monell team and colleagues identified that GLP-1 receptor agonists, a class of drugs ... suggesting a different mechanism for weight gain compared to typical obesity animal models.
SYNT-101 offers a novel approach to weight loss by temporarily altering nutrient absorption in the small intestine. Unlike ...
Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022. (HealthDay News) — Among U.S. adults without diabetes, the use of glucagon-like ...
Compounded semaglutide helps manage blood sugar and curb appetite for better diabetes control and weight loss. Learn how it ...
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...
Hydreight Technologies Expands GLP-1 Telehealth Suite with Launch of Liraglutide on VSDHOne Platform
No matter how the landscape shifts, Hydreight users can count on a complete and reliable GLP-1 portfolio.” Liraglutide is a GLP-1 receptor agonist used in the management of obesity and type 2 ...
HealthDay on MSN10d
2018 to 2022 Saw Increase in GLP-1 Receptor Agonist Use in Adults Without DiabetesHealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results